PRESS RELEASE published on 05/28/2024 at 19:00, 2 years 2 months ago JTC Team to Host the Virtual Investor Pitch Conference on June 17-18, 2024 JTC Team announces Virtual Investor Pitch Conference on June 17-18, 2024, featuring live video webcast presentations with Q&A. Participating company line-up to be revealed later Investor Relations JTC Team Virtual Investor Pitch Conference Live Video Webcast Q&A
BRIEF published on 05/23/2024 at 16:35, 2 years 2 months ago GRI Bio (NASDAQ : GRI) participe à Virtual Investor CEO Connect Relations Avec Les Investisseurs Communications D'entreprise Biographie Du GRI Investisseur Virtuel Connexion Du PDG
BRIEF published on 05/23/2024 at 16:35, 2 years 2 months ago GRI Bio (NASDAQ: GRI) Participates in Virtual Investor CEO Connect Investor Relations Corporate Communications GRI Bio Virtual Investor CEO Connect
PRESS RELEASE published on 05/23/2024 at 16:30, 2 years 2 months ago GRI Bio (NASDAQ: GRI) Participates in Virtual Investor CEO Connect JTC Team announces CEO Connect segment with GRI Bio's Marc Hertz, PhD, covering recent achievements and upcoming milestones. Virtual Investor platform offers more videos GRI Bio Virtual Investor CEO Connect JTC Team Communication Strategies
BRIEF published on 04/25/2024 at 15:50, 2 years 3 months ago Moleculin Biotech souligne le rôle de l'annamycine dans le traitement de la LMA dans le segment des investisseurs virtuels du JTC Essais Cliniques Opportunité D'investissement Biotechnologie Moléculaire Annamycine Traitement LMA
BRIEF published on 04/25/2024 at 15:50, 2 years 3 months ago Moleculin Biotech Emphasizes Annamycin's Role in AML Treatment in JTC Virtual Investor Segment Clinical Trials Investment Opportunity Moleculin Biotech Annamycin AML Treatment
PRESS RELEASE published on 04/25/2024 at 15:45, 2 years 3 months ago Moleculin Biotech (NASDAQ:MBRX) Participates in Virtual Investor "What This Means" Segment Hosted by JTC Team Moleculin CEO highlights Annamycin's differentiation in AML treatment landscape and investment opportunity. Positive interim data shared in 'What This Means' segment Investment Opportunity Clinical Trial Moleculin Biotech Annamycin AML Treatment
PRESS RELEASE published on 10/18/2023 at 16:00, 2 years 9 months ago JTC Team Announces Presenting Company Line Up for the Virtual Investor “Ask the CEO” Conference Being Held October 24-25, 2023
Published on 08/11/2026 at 14:30, 1 hour 43 minutes ago ACCESS Newswire Reports Second Quarter 2026 Results
Published on 08/11/2026 at 14:30, 1 hour 43 minutes ago AIAI Holdings' Constellation Network Launches Dôr Retail Intelligence: Transformational AI-Powered Retail Intelligence
Published on 08/11/2026 at 14:00, 2 hours 13 minutes ago First Canadian Graphite Signs Agreement with Groupe Nipi, in Collaboration with BBA, for its Preliminary Environmental Study at Lac Guéret Sud
Published on 08/11/2026 at 14:00, 2 hours 13 minutes ago First Canadian Graphite conclut une entente avec le Groupe Nipi en collaboration avec la firme BBA pour une étude environnementale préliminaire au Lac Guéret Sud
Published on 08/11/2026 at 13:30, 2 hours 43 minutes ago Nextech3D.ai CEO Evan Gappelberg Purchases 250,000 Shares in Open Market
Published on 08/11/2026 at 15:57, 15 minutes ago Medios Acquires a 74% Majority Stake in Caelo and Strengthens Its German and European Business in Active Pharmaceutical Ingredients and Excipients
Published on 08/10/2026 at 18:00, 22 hours 13 minutes ago AXA: Information relating to the number of voting rights and shares making up the share capital on 31/07/2026
Published on 08/10/2026 at 18:00, 22 hours 13 minutes ago AXA : Information relative au nombre total de droits de vote et d'actions composant le capital social au 31/07/2026
Published on 08/10/2026 at 17:45, 22 hours 28 minutes ago Déclaration hebdomadaire de rachat d'actions
Published on 08/10/2026 at 11:53, 1 day 4 hours ago GUILLEMOT CORPORATION | Information regarding the total number of voting rights and shares 31/07/2026
